Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Items 201–300 of 796
The role of neuroimaging in mild cognitive impairment
Matsuda, H. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00794.x · Cited by 108
“cates that the pathophysiologic process begins well before even mild or questionable dementia is recognized clinically.(23,24) PET measures of glucose hypometabolism reflect decreased synaptic activity due either to loss or dysfunction of synapses,(25) and regional metabolic deficits observed on PET may reflect projec…”
BackgroundSubregions of the inferior parietal lobule are affected in the progression to Alzheimer's disease
Greene, S. J., & Killiany, R. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.026 · Cited by 107
Cheung, Y. T., Lim, S. R., Shwe, M., Tan, Y. P., & Chan, A. (2013) · Value in Health · doi:10.1016/j.jval.2013.06.017 · Cited by 108
“[66] Small GW, Ercoli LM, Silverman DH, et al.”
BackgroundSpecificity of Brain Activation Patterns in People at Genetic Risk for Alzheimer Disease
Burggren, A. C., Small, G. W., Sabb, F. W., & Bookheimer, S. Y. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00006 · Cited by 116
Self-citationPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
“ApoE4 is also associated with decreased cerebral glucose metabolism in AD, indicating that a combination of cerebral metabolic rates and genetic risk factors offers a strategy for preclinical AD diagnoses (368).”
BackgroundPositron emission tomography in clinical neurology
Herholz, K., & HEISS, W. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.05.002 · Cited by 119
Barnes, J., Scahill, R. I., Schott, J. M., Frost, C., Rossor, M. N., & Fox, N. C. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000084560 · Cited by 106
“Metabolic deficits have also been shown to be higher on the left than the right in individuals with increased genetic risk of developing AD [”
BackgroundRoses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 114
Self-citationDeiana, S., Harrington, C. R., Wischik, C. M., & Riedel, G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1394-2 · Cited by 119
“ATP production. In AD, glucose metabolism is reduced by 30–50% in several brain regions implicated in cognitive functions (De Leon et al. 1983; Small et al. 2000; Arnaiz et al. 2001) and this could lower the rate of ACh synthesis (Gibson and Blass 1976).”
BackgroundThe Cerebral Response during Subjective Choice with and without Self-reference
Johnson, S. C., Schmitz, T. W., Kawahara-Baccus, T. N., Rowley, H. A., Alexander, A. L., Lee, J., & Davidson, R. J. (2005) · Journal of Cognitive Neuroscience · doi:10.1162/089892905775008607 · Cited by 106
Slow Excitotoxicity in Alzheimer's Disease
Ong, W.-Y., Tanaka, K., Dawe, G. S., Ittner, L. M., & Farooqui, A. A. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121990 · Cited by 100
“ApoE4 is associated with decreased cerebral glucose metabolism in both AD patients and non-demented subjects [94].”
Trumble, B. C., Stieglitz, J., Blackwell, A. D., Allayee, H., Beheim, B., Finch, C. E., Gurven, M., & Kaplan, H. (2017) · The FASEB Journal · doi:10.1096/fj.201601084r · Cited by 106
Caselli, R. J., Chen, K., Lee, W., Alexander, G. E., & Reiman, E. M. (2008) · Archives of Neurology · doi:10.1001/archneurol.2008.1 · Cited by 102
“The mean (SD) time from baseline FDG-PET to the first AVLT test epoch did not differ between the preMCI group (41 [23] months) and the nondecliner group Table 1.”
Aerobic glycolysis in the primate brain: Reconsidering the implications for growth and maintenance
Bauernfeind, A. L., Barks, S. K., Duka, T., Grossman, L. I., Hof, P. R., & Sherwood, C. C. (2014) · Brain Structure and Function · doi:10.1007/s00429-013-0662-z · Cited by 105
APOE alters glucose flux through central carbon pathways in astrocytes
Williams, H. C., Farmer, B. C., Piron, M. A., Walsh, A. E., Bruntz, R. C., Gentry, M. S., Sun, R. C., & Johnson, L. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104742 · Cited by 105
Use of Functional Magnetic Resonance Imaging in the Early Identification of Alzheimer's Disease
Wierenga, C. E., & Bondi, M. W. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9025-y · Cited by 116
Chatterjee, P., Fernando, M. G., Fernando, B., Dias, C. B., Shah, T. M., Silva, R., Williams, S., Pedrini, S., Hillebrandt, H., Goozee, K. G., et al. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111209 · Cited by 112
Orr, A. L., Kim, C., Jimenez-Morales, D., Newton, B. W., Johnson, J. R., Krogan, N. J., Swaney, D. L., & Mahley, R. W. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181184 · Cited by 103
Devous, M. D. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0967-2 · Cited by 109
“These studies have shown that patients with more severe perfusion or metabolic deficits in the temporoparietal or posterior cingulate cortices show more rapid cognitive decline over time [ 67 , 68, 69, 70].”
BackgroundInfluentialAltered deactivation in individuals with genetic risk for Alzheimer's disease
Persson, J., Lind, J., Larsson, A., Ingvar, M., Sleegers, K., Van Broeckhoven, C., Adolfsson, R., Nilsson, L.-G., & Nyberg, L. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.01.026 · Cited by 102
Zhu, D. C., Majumdar, S., Korolev, I. O., Berger, K. L., & Bozoki, A. C. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121879 · Cited by 103
“The PCC, or more generally the posterior cingulate cortex/retrosplenial cortex (PCC/RSC) [19], is not only part of the DMN but also shows prominent hypometabolism as one of the earliest findings on FDG-PET scans of AD and many MCI patients [4, 5, 20, 21].”
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
Mistur, R., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.4.153 · Cited by 93
Effect of parental family history of Alzheimer's disease on serial position profiles
La Rue, A., Hermann, B., Jones, J. E., Johnson, S., Asthana, S., & Sager, M. A. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.03.009 · Cited by 94
“[3] Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al.”
BackgroundNeural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging
Lee, D. H., Lee, P., Seo, S. W., Roh, J. H., Oh, M., Oh, J. S., Oh, S. J., Kim, J. S., & Jeong, Y. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.11.053 · Cited by 105
“Another study found that healthy 50–84 year old adults with ApoEε4 exhibited cerebral metabolic decline over a two-year period, which was particularly marked in the right inferior parietal lobule, and which was associated with a decline in memory performance (Small et al., 2000).”
Weinstock, M., & Shoham, S. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0058-y · Cited by 105
“Positron emission tomography has shown that glucose metabolism is reduced by 30–50% in the posterior cingulate, parietal and temporal regions of the cortex at an early stage of the disease (De Leon et al., 1983; Hoyer, 1993; Small et al., 2000; Arnaiz et al., 2001).”
BackgroundEarly functional network alterations in asymptomatic elders at risk for Alzheimer’s disease
Nakamura, A., Cuesta, P., Kato, T., Arahata, Y., Iwata, K., Yamagishi, M., Kuratsubo, I., Kato, K., Bundo, M., Diers, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06876-8 · Cited by 109
Natural history of Alzheimer’s disease
Honig, L. S., & Mayeux, R. P. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351476 · Cited by 112
Sun, Y., Wang, Y., Chen, S.-T., Chen, Y.-J., Shen, J., Yao, W.-B., Gao, X.-D., & Chen, S. (2020) · Theranostics · doi:10.7150/thno.44370 · Cited by 93
“According to the viewpoint considering AD as "type 3 diabetes", abnormal brain energy metabolism plays a pivotal role in the occurrence and development of AD [33, 34].”
BackgroundDonix, M., Burggren, A. C., Suthana, N. A., Siddarth, P., Ekstrom, A. D., Krupa, A. K., Jones, M., Rao, A., Martin-Harris, L., Ercoli, L. M., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.009 · Cited by 94
“It has been shown that there is greater decline in brain glucose metabolism when comparing middle-aged healthy APOE-4 carriers and noncarriers in a 2-year follow-up (Small et al., 2000).”
Self-citationMild cognitive impairment: Conceptual issues and structural and functional brain correlates
Saykin, A. J., & Wishart, H. A. (2003) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2003.50002 · Cited by 95
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases
Yang, S., Park, J. H., & Lu, H.-C. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00634-3 · Cited by 94
“MCI/AD Imaging: FDG‑PET for 66 AD, 23 early AD, 22 ctrl subjects Aimed to investigate cerebral glucose metabolism in early AD • Glucose uptake in PCC↓ MMSE scores↓ [42] Imaging: FDG‑PET and DTI with 20 early AD, 18 ctrl subjects Aimed to explore the association among hippocampal structural integrity, whole brain gluco…”
BackgroundApolipoprotein E genotype, gender and age modulate connectivity of the hippocampus in healthy adults
Heise, V., Filippini, N., Trachtenberg, A. J., Suri, S., Ebmeier, K. P., & Mackay, C. E. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.04.081 · Cited by 99
The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress
van der Harg, J. M., Nölle, A., Zwart, R., Boerema, A. S., van Haastert, E. S., Strijkstra, A. M., Hoozemans, J. J., & Scheper, W. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.354 · Cited by 88
“A reduced glucose metabolic rate is already observed in patients that are genetically predisposed to develop AD before any pathological signs of the diseasemanifest.(29,30) Moreover, glucose metabolism is also decreased in brains of patients with mild cognitive impairment, which is a prodromal stage of AD.”
BackgroundDiabetes, Alzheimer's disease and apolipoprotein genotype
Messier, C. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(03)00153-0 · Cited by 106
Functional Genomics of Brain Aging and Alzheimers Disease: Focus on Selective Neuronal Vulnerability
Wang, X., L. Michaelis, M., & K. Michaelis, E. (2010) · Current Genomics · doi:10.2174/138920210793360943 · Cited by 93
“Since the metabolic activity of the brain is very high, accounting for an estimated 20-25% of glucose and oxygen utilization in the body, it is not surprising that reduced metabolism and energy production might be significantly correlated with cognitive decline in AD [75, 76].”
BackgroundCerebrovascular Effects of Amyloid-ß Peptides: Mechanisms and Implications for Alzheimer's Dementia
Iadecola, C. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025092617651 · Cited by 97
“Cerebral glucose utilization (CGU), a variable reflecting neural activity, is also reduced, and is thought to reflect an impairment of neuronal function (Reiman et al., 2001; Small et al., 2000).”
Rentz, D. M., Huh, T. J., Faust, R. R., Budson, A. E., Scinto, L. F. M., Sperling, R. A., & Daffner, K. R. (2004) · Neuropsychology · doi:10.1037/0894-4105.18.1.38 · Cited by 86
“Third, recent studies have shown that individuals with initial memory impairments can remain stable for 3 to 6 years prior to receiving a diagnosis of AD and then exhibit an accelerated decline (Goldman & Morris, 2001; B. Small et al., 2000).”
BackgroundResultAge-related differences in white matter integrity and cognitive function are related to APOE status
Ryan, L., Walther, K., Bendlin, B. B., Lue, L.-F., Walker, D. G., & Glisky, E. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.08.052 · Cited by 87
Huang, T. L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-090934 · Cited by 90
“creased brain activation during recall [103].”
Head, E., Lott, I. T., Patterson, D., Doran, E., & Haier, R. J. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11110 · Cited by 89
“It must be noted, that the majority of similar neuroimaging studies of patients with early AD, MCI, and persons at risk for AD (e.g. APOE4 positive) do not show brain activity increases [122,146–148 ,167, 168”
Garrido, G. E. J. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.508 · Cited by 93
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease
Small, G., & Bullock, R. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.016 · Cited by 83
“Lowered glucose metabolism detected by positron emission tomography has been noted in brain regions (frontal, parietal, and temporal) receiving cholinergic projections, also indicative of preclinical AD neurodegenerative changes [19].”
BackgroundSelf-citationSpatial Navigation and APOE in Amnestic Mild Cognitive Impairment
Laczó, J., Andel, R., Vlček, K., Macoška, V., Vyhnálek, M., Tolar, M., Bojar, M., & Hort, J. (2010) · Neurodegenerative Diseases · doi:10.1159/000321581 · Cited by 92
In vivo human hippocampal cingulate connectivity: A corticocortical evoked potentials (CCEPs) study
Kubota, Y., Enatsu, R., González-Martínez, J., Bulacio, J. C., Mosher, J. C., Burgess, R. C., & Nair, D. R. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.01.024 · Cited by 92
“In studies of Alzheimer’s disease among a population with very early suspected Alzheimer’s disease, PET hypometabolism in posterior cingulate cortex was implicated in impairment of learning and memory (Minoshima et al., 1997; Small et al., 2000).”
BackgroundApolipoprotein E ε4 modulates functional brain connectome in Alzheimer's disease
Wang, J., Wang, X., He, Y., Yu, X., Wang, H., & He, Y. (2015) · Human Brain Mapping · doi:10.1002/hbm.22740 · Cited by 86
“Additionally, APOE E4 also lowers cerebral metabolism in most of the aforementioned hub regions [Reiman et al., 2004; Small et al., 2000], which is important for the high connectivity of hubs [Liang et al., 2013; Tomasi et al., 2013].”
BackgroundImaging is superior to cognitive testing for early diagnosis of Alzheimer’s disease
ZAMRINI, E. Y., Santi, S. D., & Tolar, M. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.009 · Cited by 96
“[73], found a single copy of the APOE-4 allele was associated with lower inferior parietal, lateral temporal and posterior cingulate metabolism which predicted cognitive decline after two years of longitudinal follow-up.”
BackgroundXu, G., Mclaren, D. G., Ries, M. L., Fitzgerald, M. E., Bendlin, B. B., Rowley, H. A., Sager, M. A., Atwood, C., Asthana, S., & Johnson, S. C. (2008) · Brain · doi:10.1093/brain/awn254 · Cited by 94
“Our finding is consistent with previous PET studies in which persons with high risk for developing Alzheimer's disease showed reduced glucose metabolism in PCC (Small et al., 2000; Mosconi et al., 2008b) and decreased cerebral perfusion in the precuneus (Xu et al., 2007).”
Qiu, Z., Crutcher, K. A., Hyman, B. T., & Rebeck, G. W. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.017 · Cited by 92
“In addition, positron emission tomography studies suggest that cerebral glucose metabolism is impaired in APOE-e4 individuals (Mielke et al., 1998; Small et al., 2000; Reiman et al., 2001).”
BackgroundFarmer, B. C., Williams, H. C., Devanney, N. A., Piron, M. A., Nation, G. K., Carter, D. J., Walsh, A. E., Khanal, R., Young, L. E. A., Kluemper, J. C., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00483-y · Cited by 87
Roses, A. D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s340 · Cited by 86
“…and SmithKlineBeecham] and has led to one of several AD programs active within the company – some novel, some based on amyloid involvement, and one based on the differences found in protein expression between brain tissue expressing neuronal human apoE4 and tissue expressing neuronal apoE3 [25,26].”
InfluentialSelf-citationMitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease
Butterfield, D. A., & Boyd-Kimball, D. (2020) · Antioxidants · doi:10.3390/antiox9090818 · Cited by 85
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes
Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-3-170 · Cited by 85
Adluru, N., Destiche, D. J., Lu, S. Y.-F., Doran, S. T., Birdsill, A. C., Melah, K. E., Okonkwo, O. C., Alexander, A. L., Dowling, N. M., Johnson, S. C., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.04.008 · Cited by 85
Hoscheidt, S. M., Starks, E. J., Oh, J. M., Zetterberg, H., Blennow, K., Krause, R. A., Gleason, C. E., Puglielli, L., Atwood, C. S., Carlsson, C. M., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160110 · Cited by 81
“APOE 4 carriage is associated with hypometabolism [38–40], higher amyloid burden [41] and gray matter atrophy in AD-sensitive regions [42], and as shown by animal studies, may be particularly deleterious to the hippocampus and hippocampal-dependent tasks such as the Morris water maze, object recognition, and context f…”
L-arginine and Alzheimer's disease.
Yi, J., Horky, L. L., Friedlich, A. L., Shi, Y., Rogers, J. T., & Huang, X. (2009) · PubMed Central · Cited by 95
Working memory and FDG–PET dissociate early and late onset Alzheimer disease patients
Kalpouzos, G., Eustache, F., Sayette, V. D. L., Viader, F., Chételat, G., & Desgranges, B. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0685-3 · Cited by 92
“5; 12 mm), according to the procedure described elsewhere [54].”
The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 92
Mapping genetic influences on human brain structure
Thompson, P., Cannon, T. D., & Toga, A. W. (2002) · Annals of Medicine · doi:10.1080/078538902321117733 · Cited by 81
Fluorodeoxyglucose PET in Neurology and Psychiatry
Schöll, M., Damián, A., & Engler, H. (2014) · PET Clinics · doi:10.1016/j.cpet.2014.07.005 · Cited by 86
Rasgon, N. L., Geist, C. L., Kenna, H. A., Wroolie, T. E., Williams, K. E., & Silverman, D. H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089095 · Cited by 82
“in middle-aged and older persons at genetic risk for AD [55].”
BackgroundSelf-citationBrain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease
Mosconi, L. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.014993 · Cited by 83
Small, S. A., Wu, E. X., Bartsch, D., Perera, G. M., Lacefield, C. O., DeLaPaz, R., Mayeux, R., Stern, Y., & Kandel, E. R. (2000) · Neuron · doi:10.1016/s0896-6273(00)00144-6 · Cited by 85
Crivello, F., Lemaître, H., Dufouil, C., Grassiot, B., Delcroix, N., Tzourio‐Mazoyer, N., Tzourio, C., & Mazoyer, B. M. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.12.116 · Cited by 90
“Moreover, positron emission tomography studies have shown a temporal hypometabolism in nondemented heterozygotes compared to noncarriers (Small et al., 2000; Reiman et al., 2001).”
Optimization of 13C isotopic tracers for metabolic flux analysis in mammalian cells
Walther, J. L., Metallo, C. M., Zhang, J., & Stephanopoulos, G. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2011.12.004 · Cited by 75
“In particular, interest in the metabolic analysis of mammalian systems has increased of late, as metabolic defects have been implicated in cancer, mental disorders, diabetes, and related syndromes (AbouSleiman et al., 2006; Biddinger and Kahn, 2006; Christofk et al., 2008; Small et al., 2000).”
BackgroundOverlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes
Ahmad, W. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8352-z · Cited by 86
Liang, W. S., Dunckley, T. L., Beach, T. G., Grover, A., Mastroeni, D., Ramsey, K. M., Caselli, R. J., Kukull, W. A., McKeel, D. W., Morris, J. C., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.013 · Cited by 86
“…and Braak, 1991; irra et al., 1991; Thal et al., 2002) and metabolic deficits Blesa et al., 1996; Jack et al., 1998; Mielke et al., 1994, 1998; mall et al., 2000) in the MTG and PC. Dendrograms listing enes demonstrating the greatest expression changes in both DAD and AD brains compared to…”
BackgroundMaki, P. M., & Dumas, J. A. (2009) · Seminars in Reproductive Medicine · doi:10.1055/s-0029-1216278 · Cited by 89
“This pair of investigations demonstrates that estrogen therapy is associated with reliably enhanced neural activity in posterior cingulate cortex, a region showing early decreases in metabolism in Alzheimer patients and in healthy individuals with a genetic risk factor for Alzheimer’s disease.(31) Effects in other bra…”
BackgroundJin, M., Pelak, V. S., & Cordes, D. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2011.07.007 · Cited by 77
“The diagnosis of AD is typically preceded by a long prodromal phase during which a person has detectable cognitive deficits (mild cognitive impairment, or MCI) but does not meet the criteria for dementia [38,39].”
BackgroundR6/2 Huntington's Disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures
Cepeda-Prado, E., Popp, S., Khan, U., Stefanov, D., Rodríguez, J., Menalled, L. B., Dow-Edwards, D., Small, S. A., & Moreno, H. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0388-12.2012 · Cited by 82
“In vivo measurement of local glucose utilization As established by numerous studies (Reiman et al., 1996; Costa et al., 1999; Rapoport, 2000; Small et al., 2000a,b; Dixon et al., 2002; El Fakhri et al., 2003), rCBV is a correlate of oxygen consumption and therefore typically reflects regional…”
Alzheimer's Disease: Neuropathologic Findings and Recent Advances in Imaging
Norfray, J. F., & Provenzale, J. M. (2004) · American Journal of Roentgenology · doi:10.2214/ajr.182.1.1820003 · Cited by 88
Alzheimer Risk Variant CLU and Brain Function During Aging
Thambisetty, M., Beason-Held, L. L., An, Y., Kraut, M., Nalls, M., Hernandez, D. G., Singleton, A. B., Zonderman, A. B., Ferrucci, L., Lovestone, S., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.026 · Cited by 75
“Most of these studies have been cross sectional, and the most consistent observations were that of reductions in cerebral metabolic rate of glucose consumption in the temporal and parietal cortices (21, 22).”
BackgroundActivated astrocytes: a therapeutic target in Alzheimer’s disease?
Fuller, S., Münch, G., & Steele, M. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.111 · Cited by 77
Batista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 77
Beta2-Adrenergic Receptor and Astrocyte Glucose Metabolism
Dong, J., Chen, X., Cui, M., Yu, X., Pang, Q., & Sun, J. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9742-4 · Cited by 83
Mosconi, L. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.030882 · Cited by 76
APOE and Alzheimer’s Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction
Brandon, J. A., Farmer, B. C., Williams, H. C., & Johnson, L. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00180 · Cited by 75
“A reduction in cerebral metabolic rate of glucose (CMRglc), as measured by FDG-PET, is now considered one of the hallmarks of AD (Small et al., 2000).”
BackgroundRedel, P., Bublak, P., Sorg, C., Kurz, A., Förstl, H., Müller, H. J., Schneider, W. X., Perneczky, R., & Finke, K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.014 · Cited by 80
Clinical application of positron emission tomography for diagnosis of dementia
Ishii, K. (2002) · Annals of Nuclear Medicine · doi:10.1007/bf02988628 · Cited by 79
Baxter, L. C., Caselli, R. J., Johnson, S. C., Reiman, E. M., & Osborne, D. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00006-x · Cited by 79
“In another longitudinal study, a 5% decline in lateral temporal and parietal cortices was significant for ε4 heterozygotes [23].”
BackgroundReassessment of Pioglitazone for Alzheimer’s Disease
Saunders, A. M., Burns, D. K., & Gottschalk, W. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.666958 · Cited by 63
Self-citationProteome-Based Plasma Markers of Brain Amyloid-β Deposition in Non-Demented Older Individuals
Thambisetty, M., Tripaldi, R., Riddoch-Contreras, J., Hye, A., An, Y., Campbell, J., Sojkova, J., Kinsey, A., Lynham, S., Zhou, Y., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101350 · Cited by 72
“…subsequent validation-phase experiments was based both on the relatively large contribution from this protein to the PLS-DA model for brain amyloid, and the substantial body of evidence implicating both the APOE gene and ApoE protein in several aspects of AD pathogenesis [18,19,21,22,29, 37,41].”
The role of inflammatory processes in Alzheimer’s disease
Broussard, G. J., Mytar, J. O., Li, R., & Klapstein, G. J. (2012) · Inflammopharmacology · doi:10.1007/s10787-012-0130-z · Cited by 75
The future of fMRI and genetics research
Meyer‐Lindenberg, A. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.10.063 · Cited by 79
“…showing an association of common genetic variants in human brain function were obtained (Egan et al., 2001; Hariri et al., 2002; Heinz et al., 2000; Small et al., 2000), I could see that almost from the very beginning, geneticists were skeptical whether single variants could have effects that big,…”
BackgroundTemporal cortex hypermetabolism in Down syndrome prior to the onset of dementia
Haier, R. J., Alkire, M. T., White, N. S., Uncapher, M. R., Head, E., Lott, I. T., & Cotman, C. W. (2003) · Neurology · doi:10.1212/01.wnl.0000098935.36984.25 · Cited by 70
Apolipoprotein E, cardiovascular disease and cognitive function in aging women
Kang, J. H., Logroscino, G., Vivo, I. D., Hunter, D. J., & Grodstein, F. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.003 · Cited by 77
State of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0814 · Cited by 70
Pardon, M., & Rattray, I. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.005 · Cited by 77
An update on drug treatment options of Alzheimer's disease
Allgaier, M. (2014) · Frontiers in Bioscience · doi:10.2741/4285 · Cited by 69
“(2000) (31) carriers of APO-E epsilon4 who developed AD have lowered parietal, temporal and posterior cingulate glucose levels, leading to significant cognitive impairment”
BackgroundUse of medical foods and nutritional approaches in the treatment of Alzheimer’s disease
Thaipisuttikul, P., & Galvin, J. E. (2012) · Clinical Practice · doi:10.2217/cpr.12.3 · Cited by 69
Developmental origins of aging in brain and blood vessels: an overview
Finch, C. E. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.015 · Cited by 75
Jin, N., Qian, W., Yin, X., Zhang, L., Iqbal, K., Grundke-Iqbal, I., Gong, C.-X., & Liu, F. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1227 · Cited by 67
Harrison, T. M., Mahmood, Z., Lau, E. P., Karacozoff, A. M., Burggren, A. C., Small, G. W., & Bookheimer, S. Y. (2016) · eNeuro · doi:10.1523/eneuro.0098-16.2016 · Cited by 73
“the recruitment of 40–50% of participants carrying at least one copy of the APOE 4 allele, which is greater than the 20-25% that would be expected from purely random recruitment (Bookheimer et al., 2000; Small et al., 2000).”
BackgroundSelf-citationMitochondrial Metabolism in Major Neurological Diseases
Zhou, Z., Austin, G. L., Young, L. E. A., Johnson, L. A., & Sun, R. C. (2018) · Cells · doi:10.3390/cells7120229 · Cited by 73
“Since these initial findings in the early 1980s, a multitude of additional studies have confirmed the phenomena, and a reduction in the cerebral metabolic rate of glucose (CMRglc), as measured by FDG-PET, is now considered one of the hallmarks of AD [78].”
BackgroundPerry, R. J., & Hodges, J. R. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02754.x · Cited by 64
Wang, Y., Mishra, A., & Brinton, R. D. (2020) · F1000Research · doi:10.12688/f1000research.21599.1 · Cited by 61
Interaction between years of education and APOE ε4 status on frontal and temporal metabolism
Arenaza-Urquijo, E. M., Gonneaud, J., Fouquet, M., Perrotin, A., Mézenge, F., Landeau, B., Egret, S., De la Sayette, V., Desgranges, B., & Chételat, G. (2015) · Neurology · doi:10.1212/wnl.0000000000002034 · Cited by 64
Functional Foods: An Approach to Modulate Molecular Mechanisms of Alzheimer’s Disease
Atlante, A., Amadoro, G., Bobba, A., & Latina, V. (2020) · Cells · doi:10.3390/cells9112347 · Cited by 73
“Researchers speculate that genetic risk factors can be responsible only for one third of how our brain changes with age [3,4].”
BackgroundGibson, G. E. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00802-x · Cited by 76
Hypometabolism, Alzheimer’s Disease, and Possible Therapeutic Targets: An Overview
Raut, S., Bhalerao, A., Powers, M., Gonzalez, M., Mancuso, S., & Cucullo, L. (2023) · Cells · doi:10.3390/cells12162019 · Cited by 65
Temporal Dynamics of Brain Anatomy
Toga, A. W., & Thompson, P. M. (2003) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.5.040202.121611 · Cited by 66
“, 2001), or in those at genetic risk for Alzheimer’s disease (Small et al., 2000; Lehtovirta et al., 2000).”
Background
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.